CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE

Their core work

CHU Lille is one of France's largest university hospitals, combining clinical care with translational research across neurology, oncology, immunotherapy, and metabolic diseases. In H2020, they contribute clinical trial infrastructure, patient cohorts, and specialist medical expertise — particularly in neurodegenerative diseases (Parkinson's, brain research) and immunotherapy for cancers like mesothelioma and multiple myeloma. They are a long-standing partner in the Human Brain Project, providing clinical neuroscience data and expertise on biological signatures of disease. Their work bridges bedside medicine and large-scale research infrastructure, making them a key clinical validation site for European health research.

What they specialise in

How they've shifted over time

In their early H2020 period (2015-2017), CHU Lille focused on disease-specific clinical research — Parkinson's disease trials, mesothelioma immunotherapy, Ebola vaccines, and diabetes — while beginning their involvement in the Human Brain Project. From 2018 onward, their portfolio shifted decisively toward computational neuroscience and brain research infrastructure (HBP SGA2, SGA3, ICEI), hypothalamic biology (WATCH, miniNO, REPRODAMH), and large-scale data-driven health research like obesity stratification. The clinical trial work remained but became less dominant compared to their growing role as a neuroscience research node within European e-infrastructures.

CHU Lille is increasingly positioned as a clinical neuroscience hub within large European brain research infrastructures, with growing emphasis on hypothalamic biology, computational neuroscience, and federated health data systems.

How they like to work

CHU Lille operates almost exclusively as a participant or third-party contributor rather than a consortium leader — they coordinated only 1 of 17 projects (FAIR-PARK-II). They consistently join large, multi-partner consortia (292 unique partners across 27 countries), which reflects their role as a clinical site contributing patient data, trial infrastructure, and specialist medical knowledge. This makes them a reliable, low-friction partner for large-scale health projects that need a top-tier French university hospital in their consortium.

CHU Lille has collaborated with 292 unique partners across 27 countries, largely through participation in very large consortia like the Human Brain Project. Their network is pan-European with strong ties to major research hospitals, neuroscience institutes, and pharmaceutical partners across Western Europe.

What sets them apart

CHU Lille combines the clinical infrastructure of a major French university hospital (patient cohorts, trial sites, clinical data) with deep involvement in Europe's flagship computational neuroscience initiative (Human Brain Project / EBRAINS). This dual positioning — bedside clinical expertise plus large-scale brain simulation and data infrastructure — is rare among hospital participants. For consortium builders, they offer immediate access to French clinical populations alongside established connections to the EBRAINS research infrastructure ecosystem.

Highlights from their portfolio

• FAIR-PARK-II
  Their only coordinated project and largest budget (EUR 2.6M) — a multicentric clinical trial testing iron chelation as a disease-modifying strategy for Parkinson's disease.
• HBP SGA3
  Third consecutive phase of the Human Brain Project, Europe's flagship brain research initiative — demonstrates sustained commitment and trusted partner status in this massive infrastructure effort.
• CorDial-S
  A COVID-19 rapid response project developing portable biosensor diagnostics — shows the hospital's ability to pivot quickly to emerging health threats using nanobody-based detection technology.